Investor Overview

Corporate Profile

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Latest News

May 15, 2018

Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018more >

May 14, 2018

Oncobiologics Announces $15 Million Private Placement Offeringmore >

April 17, 2018

Oncobiologics Appoints Randy Thurman to Board of Directorsmore >

Upcoming Events

There are currently no events scheduled.